Although the mechanism of action of IFN-β in MS is currently unclear, some have speculated that the efficacy of this therapy is achieved by inhibiting the function of T Helper (TH) 17 cells [4,5,6]. This evidence concerns the gene IFNB1 and myeloid sarcoma.